FDA posts press releases and other notices of recalls and market withdrawals from the firms involved as a service to consumers, the media, and other interested parties. FDA does not endorse either the product or the company.
The Ritedose Corporation Announces the Voluntary Nationwide Recall of 0.083% Albuterol Sulfate Inhalation Solution, 3 mL Due to Mislabeled Unit Dose Vials Contact: The Ritedose Corporation 803-935-3995
FOR IMMEDIATE RELEASE - December 30, 2010 - The Ritedose Corporation is conducting a voluntary recall of 0.083% Albuterol Sulfate Inhalation Solution, 3 mL (in 25, 30, and 60 unit dose vials). This product is a prescription inhalation solution, administered via nebulization, for the treatment and maintenance of acute asthma exacerbations and exercise induced asthma in children and adults. This product is being recalled because the 2.5 mg/3 mL single use vials are embossed with the wrong concentration of 0.5 mg/ 3 mL and therefore, represents a potential significant health hazard. The following lot numbers manufactured by The Ritedose Corporation under NDC: 0591-3797-83, 0591-3797- 30, and 0591-3797-60 are included in the recall: 0N81, 0N82, 0N83, 0N84, 0NE7, 0NE8, 0NE9, 0NF0, 0P12, 0P13, 0P46, 0P47, 0PF0, and 0S15. No other Albuterol formulations or products are included in this recall. The product is packaged as a single use unit dose vials in a protective foil overwrap packaged in a shelf carton. Only the unit dose vials are incorrectly embossed as containing 0.5 mg/3 mL. The correct concentration of 2.5 mg/3 mL is labeled on the primary foil overwrap pouches and shelf cartons. This product was distributed nationwide and Puerto Rico. Administration of this defective product could result in a range of potential health effects that spans from temporary and medically reversible to life threatening and death. There is significant concern that health professionals who read the incorrect embossed concentration may upwardly adjust the volume of product used resulting in an administered amount that is 5 times the recommended dose. In the hospital setting, the vials are often not accompanied by the rest of the packaging, making it more likely that such a dosing error could occur. Significant overdosing of a patient could lead to signs and symptoms of albuterol toxicity, which includes tremors, dizziness, nervousness, headache, seizures, angina, high blood pressure, low potassium levels, and rapid heart rates up to 200 beats/minute. The Ritedose Corporation is working cooperatively with the U.S. FDA to implement a nationwide recall as quickly and efficiently as possible. Consumers should immediately return the affected product to the place it was obtained (i.e. doctor’s office, pharmacy, etc.). Wholesalers and retailers should return the product to the following address:
For more information concerning this recall contact The Ritedose Corporation directly at phone: 803-935-3995 Monday through Friday 8am to 5 pm EST or by e-mail:Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program online, or regular mail or by fax.
• Regular Mail: use postage-paid, pre-addressed Form FDA 3500 available at:
. Mail to address on the pre-addressed form.
• Fax: 1-800-FDA-0178
Man gets jail term in bicycle accident Driver had left injured cyclist unconscious on the road By Linda Thomson Deseret News Published: Friday, Oct. 30, 2009 10:48 p.m. MDT Herm Franks Jr. was an enthusiastic athlete until a driver slammed into him on his bike in March, got out and peered at the unconscious Franks on the road. The driver then raced off to hide the car and lie low from
Evidence for the Use of Intramuscular Injections in Outpatient Practice MARK SHATSKY, DO, Providence Medical Group, Portland, Oregon There are few studies comparing the outcomes of patients who are treated with oral versus intramuscular antibiotics, corticosteroids, nonsteroidal anti-inflammatory drugs, or vitamin B . This may lead to confusion about when the intramuscular route is indica